Brightmind AI

Brightmind AI capitalizes on advanced transcranial magnetic stimulation (TMS) combined with artificial intelligence to innovate the treatment of brain health from the comfort of home. This  AI mental health  device tackles a spectrum of neurological conditions, such as migraines, mental decline, and mood disorders, through a user-friendly, non-invasive approach. Notably, it has been effective in reducing migraine frequency by over half in nearly 90% of its users, presenting a significant enhancement over existing options. The  AI for Healthcare  technology customizes treatments by adapting to the unique neural patterns of each user, fostering optimal brain health. By making sophisticated neurological treatments simple and accessible, Brightmind AI promises to transform how individuals manage brain health, bringing expert care into everyday settings.

Brightmind AI leverages state-of-the-art AI and transcranial magnetic stimulation (TMS) technology, offering a range of applications:

• Migraine Management: Brightmind AI has fine-tuned methods that substantially cut down the occurrence of migraine headaches. Research indicates their TMS treatment can halve migraine episodes in a vast majority of patients, providing an alternative for those inadequately helped by conventional methods.

• Treatment of Neurological Conditions: This tool is also engineered to assist with broader neurological issues such as mental decline and mood disorders, serving as a multifunctional device in neurotherapy.

• Ongoing Research and Development: Brightmind AI is deeply involved in advancing its applications through rigorous research and expansive clinical trials. They are currently examining the efficacy of their next-gen device across broader neurological applications.

These use cases underscore Brightmind AI’s dedication to pushing the boundaries of technology to foster better brain health and improve quality of life for individuals facing neurological conditions.

Brightmind AI provides its cutting-edge transcranial magnetic stimulation device at no cost, ensuring that advanced neurological therapies are accessible to a broader audience. This policy of not charging for the device eliminates economic obstacles, promoting a more inclusive reach. Such accessibility allows a diverse range of individuals to utilize this pioneering technology, seamlessly incorporating it into their regular healthcare routines. By making the device available for free, Brightmind AI helps speed up the widespread adoption of their neurotechnology, which is designed to enhance the lives of people dealing with migraines, mood disorders, and cognitive impairments. Their dedication to providing free access to innovative health solutions underscores their mission to globally improve brain health and democratize access to the latest medical technologies.

The Brightmind AI ensemble features experts from various sectors, each contributing vital expertise to the development and implementation of their transcranial magnetic stimulation technology. René Gilvert holds the position of Co-Founder and CEO, steering the strategic direction of the company. Tamara Gerbert, Founder and Vice President of Strategy, also oversees the Neuroscience department, ensuring that the firm’s technological progress is rooted in rigorous scientific validation. Dr. Gregor Kowarik, also a Co-Founder and the Chief Technology Officer, is dedicated to the technical and product enhancement aspects of their offerings.



René Gilvert

Co-Founder & CEO



Tamara Gerbert

Founder, VP of Strategy & Director of Neuroscience



Dr. Gregor Kowarik

Co-Founder & CTO

Dr. Luca Ticini holds the position of Chief Scientific Officer (CSO), spearheading research initiatives, while Uzair Rashid as the Chief Commercial Officer (CCO) drives the commercial strategy and business growth. Theresa Winkler, as the Director of Commercial Operations, manages the business operations efficiently.



Dr. Luca Ticini

CSO



Uzair Rashid

CCO



Theresa Winkler

Director of Commercial Operations

The team also includes specialized roles such as Diego Milardovich, PhD, an AI Specialist who integrates advanced machine learning techniques into their technology, and Florian Lerchbammer-Kreith, an Advising Co-Founder, who lends his expertise in MedTech to the team. Dr. Rand Almajidy, a Medical Engineer, and Paul Batthyany, a Mechanical Engineer, contribute their engineering expertise to enhance the design and functionality of the devices.



Diego Milardovich, PhD

AI Specialist



Florian Lerchbammer-Kreith

Advising Co-Founder



Dr. Rand Almajidy

Medical Engineer



Paul Batthyany

Mechanical Engineer

Together, this interdisciplinary team is navigating the company through crucial phases including prototype development, clinical trials, and market launch, ensuring the technology is both effective for migraine prevention and user-friendly for at-home use.

Brightmind AI has successfully raised a total of $3 million through four funding events. The most recent capital infusion was an $800,000 grant awarded on May 8, 2024. Previously, on April 1, 2023, Brightmind AI had garnered another grant of €600,000. Their Pre Seed funding round on September 30, 2022, brought in €800,000 from xista science ventures, who are the main investors and also led this particular round. An additional grant of €800,000 was obtained on September 15, 2022. Xista science ventures has been instrumental in supporting Brightmind AI's growth, having actively participated in these financial rounds to propel the company's development forward.